XML 46 R29.htm IDEA: XBRL DOCUMENT
v3.3.1.900

INTANGIBLE ASSETS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of intangible assets | The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:
|  | December 31, 2015 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OPERA® software patent |  | $ | 31,951 |  |  | $ | (4,493 | ) |  | $ | 27,458 |  |  |  | 13.75 |
Development costs of corporate website |  |  | 91,743 |  |  |  | (91,743 | ) |  |  | — |  |  |  | n/a |
Approved hormone therapy drug candidate patents |  |  | 705,752 |  |  |  | (49,845 | ) |  |  | 655,907 |  |  |  | 17 |
Hormone therapy drug candidate patents (in process) |  |  | 774,165 |  |  |  | — |  |  |  | 774,165 |  |  |  | n/a |
Non-amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks for vitamins/supplements |  |  | 157,721 |  |  |  | — |  |  |  | 157,721 |  |  |  | indefinite |
Total |  | $ | 1,761,332 |  |  | $ | (146,081 | ) |  | $ | 1,615,251 |  |  |  |  |
|  | December 31, 2014 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Amount |  |  | Weighted- Average Remaining Amortization Period (yrs.) |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OPERA® software patent |  | $ | 31,951 |  |  | $ | (2,496 | ) |  | $ | 29,455 |  |  |  | 14.75 |
Development costs of corporate website |  |  | 91,743 |  |  |  | (91,743 | ) |  |  | — |  |  |  | n/a |
Approved hormone therapy drug candidate patents |  |  | 439,184 |  |  |  | (19,401 | ) |  |  | 419,783 |  |  |  | 18 |
Hormone therapy drug candidate patents (in process) |  |  | 675,982 |  |  |  | — |  |  |  | 675,982 |  |  |  | n/a |
Non-amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multiple trademarks for vitamins/supplements |  |  | 103,368 |  |  |  | — |  |  |  | 103,368 |  |  |  | indefinite |
Total |  | $ | 1,342,228 |  |  | $ | (113,640 | ) |  | $ | 1,228,588 |  |  |  |  |
Schedule of estimated amortization expense | Estimated amortization expense for the next five years is as follows:
Year Ending December 31, |  |  | Estimated Amortization |
| 2016 |  |  | $ | 40,580 |
| 2017 |  |  | $ | 40,580 |
| 2018 |  |  | $ | 40,580 |
| 2019 |  |  | $ | 40,580 |
| 2020 |  |  | $ | 40,580 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration